Northwest Biotherapeutics makes changes to management team
Linda Powers becomes chief executive
Linda Powers, who has been chairman since May 2007, has become chief executive, while Dr Anthony Maida, a senior executive in the field of cancer immune therapies, is joining the company as chief operating officer on 20 June.
Dr Alton Boynton, the scientific founder of NWBT and chief executive since May 2007, is returning to the position of chief scientific officer.
Les Goldman, a former partner at US law firm Skadden, Arps, specialising in advanced technology commercialisation, has been appointed as senior vice president, business development. Dr Marnix Bosch will continue in his role as chief technology officer.
You may also like
Research & Development
Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development
Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
Regulatory
NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions
New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Manufacturing
Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025
The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Pharmaceutical
Pharma leaders to join together to shape the future of the industry at CPHI Frankfurt Leadership Summit
As the pharmaceutical industry enters a defining period of transformation, Informa Markets is hosting an exclusive Leadership Summit at this year’s CPHI Frankfurt, bringing together some of the sector’s most influential executives to address the challenges and opportunities shaping global healthcare